TCTR20210930001Active, not recruitingPhase 4
ow Dose Intravenous Zoledronate for the Treatment of Post-menopausal Osteoporosis: a prospective open-labeled study
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Active, not recruiting
- Sponsor
- Phramongkutklao hospital
- Enrollment
- 36
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40 Years to 90 Years (—)
- Sex
- Female
Inclusion Criteria
- •postmenopausal osteoporotic women from the Internal Medicine and Rheumatology Outpatient Clinic, Phramongkutklao Hospital between July 2018 and December 2019. In all the women, menopause had occurred at least five years previously, either naturally or as the result of bilateral oophorectomy. Osteoporosis is defined according to the WHO criteria, as a BMD either at the lumbar spine or hip of less than 2.5 standard deviations or more below the average value for young healthy women (a T-score of <-2.5 SD).
Exclusion Criteria
- •patients who previously received anti-resorptive treatment including bisphosphonate, estrogen replacement therapy, calcitonin and raloxifene, moderate to severe renal impairment (GFR < 35 mL/min estimated by CKD-EPI equation,8 allergic to bisphosphonates, planning for invasive dental surgery within 12 months after Zoledronate infusion, history of atrial fibrillation, history of hyperparathyroidism, vitamin D insufficiency and evidence of secondary osteoporosis.
Investigators
Similar Trials
Completed
Not Applicable
The efficacy and safety of treatment with zoledronic acid in patients and the influence of patient characteristics.Primary osteoporosisJPRN-UMIN000042547Koenji Orthopedics Clinic88
Recruiting
Phase 2
A phase II clinical trial of zoledronic acid treatment for advanced non-small cell lung cancer with bone metastasis.on-small cell lung cancerJPRN-UMIN000006935Dokkyo Medical University School of Medicine, Department of Pulmonary Medicine and Clinical Immunology40
Completed
Phase 4
Zoledronate and fracture prevention in early postmenopausal womeMusculoskeletal - OsteoporosisOsteoporosisACTRN12612000270819Dr Mark Bolland1,054
Completed
Unknown
A new study to minimise the side effects of rapid maxillary expansioSide effects of rapid maxillary expansion (RME) on dental and buccal alveolar bone changesOral HealthISRCTN16744226Damascus University32
Completed
Not Applicable
A randomized phase III study of i.v. zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma. A phase III study.Multiple MyelomaNL-OMON26780Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON)P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 4391568Fax: 010 4391028e-mail: hdc@erasmusmc.nl407